Search company, investor...

SOLX

solx.com

Stage

Dead | Dead

Total Raised

$11.74M

About SOLX

SOLX has developed a surgical laser and method of treatment for glaucoma, the second most common cause of blindness in the elderly. SOLX's DeepLight Glaucoma Treatment System is being developed to provide physicians with new tools to reduce intraocular pressure in glaucoma sufferers through its DeepLight 790 Titanium Sapphire Laser and DeepLight Gold Micro-Shunt (GMS).

Headquarters Location

230 Second Ave Suite 120

Waltham, Massachusetts, 02451,

United States

781-609-2016

Missing: SOLX's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SOLX's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing SOLX

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SOLX is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,565 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Latest SOLX News

Solana-based DEX Soldex AI: An interview with CEO John Robertson

Oct 6, 2021

It is no surprise that with wider cryptocurrency adoption things are moving faster and faster in the blockchain world. And it became very clear that the cryptocurrency exchange market is evolving rapidly, which led to the demand of new technologies being implemented. Soldex AI is hoping to take its users to the next step of crypto exchange evolution by giving users the amount of engagement never seen before. In an interview with the CEO of Solana-based DEX Soldex AI John Robertson, we are getting to know more about Unique Trading Algorithms and the abundance of benefits of the new technology. Firstly, could you please  introduce Soldex AI to the trading community? What motivated your team to develop Soldex AI? Soldex AI is a state-of-the-art hybrid crypto exchange protocol that runs on the Solana Blockchain. One of the reasons for the creation of Soldex AI is to have a third-generation exchange to solve the issues caused by order-matching centralised exchanges and trust-less custody found in current decentralised exchanges. The reason for Soldex AI protocol creation is to power the new wave of flexible financial markets. The protocol serves as a foundational layer for the settlement, custody, market making, and liquidity. Since the protocol is based on the Solana Network, it can solve problems commonly found within other Ethereum based DEXs. Using this new platform, users will exchange tokens at a speed greater than 50,000 transactions per second. All this will be done at the average cost of $0.00025 per transaction, reportedly enabling efficient and quick transactions. 2. What are the highlights and uniqueness of Soldex AI technology? Soldex AI is not only creating a DEX on Solana Blockchain but provides the flexibility for creating AI trading bots for automating each unique trading strategy. Traders will have the possibility of 24/7 trading and receiving maximum results. Later on developers will be able to lend the trading bot for success commissions. This would provide the community of incentives for further development of Soldex AI through voting rights. 3. AI bots? sounds interesting, could you elaborate a bit more? We see a huge demand for automating trading. 80% of traders loose due to human error. Every trader will be able to choose what strategy suits them best. That is why we are developing different bots with custom criteria: -Trading Risk 4. What made you choose the Solana for the blockchain. Soldex AI is being built Solana network. Since the Solana is still a relatively recent network, it has some technical improvements compared to other well know open-source blockchains like Ethereum. The main advantages of Solana over Ethereum: –   Trades Per Second (TPS) on Solana are 65,000 while Ethereum only boasts 30 Transaction fee on Solana is only $0.00001 while on Ethereum it is around $12.76 Block time on Solana is 0.4 second, while in comparison, Ethereum has staggering 15 seconds 5. In your opinion, why should the new traders join your exchange, what would be the biggest conveniences. The very first thing that the new and old traders should recognise is its technical prominence due to it being built on Solana network, it guarantees rapidness of the trades and unimaginable technical capabilities in a future . In addition, we are all familiar with the hassles that the new enthusiasts have to go trough while opening an account on the exchange. We managed to find a way to avoid all of this drag, Soldex AI is completely permission-less, so absolutely anyone, anywhere can engage in trading, providing liquidity, and staking. There is also no KYC requirement – so you don’t need to send ID or bank details to start trading. We think that the new and old traders alike will find this very practical and promising. 6. Could you tell us more on SOLX tokenomics? Soldex AI  plans to build a platform rake in millions with a revenue structure that is transparent, fair and profitable. In order to achieve this goal Soldex AI will use native Solana token – Soldex AI (SOLX). The biggest chunk of the tokens will go trough a private sale, that would be 30%. Next there will be around 5% will go on a public sale. 14% will be liquidity and the rest will go to developing team, advisors and etc. 7. The project itself looks very promising, however why people should buy SOLX, what uses it will have? The SOLX token can be used for governance rights, paying transaction fees and staking for profits. We envisioned a bright future for the token and we are sure that list of the usage will grow as Solana offers great opportunities for the improvements in the future. 8. What is Soldex AI academy and its goals? The ultimate goal of Soldex AI academy is to build a strong and vibrant Solana DeFi community. Our Vision is to be an educational resource, designed to help new users become familiar with Solana and DeFi and its key concepts. Soldex AI hopes to use this academy to explain Solana and DeFi to anyone new to the technology, help new developers to start building, learn and expose to the technology offered by the Solana, showcase resources created by the community, and build a united and impactful community. 9. Is there any vesting schedule for token holders? All private sales for serious projects have vesting to stop people dumping their tokens and crashing the price on day one of trading. SOLX vesting schedule is 20% upon payment and the balance vesting monthly at 10% per month after the TGE. 10. Is there any chance for retail to join SOLX private sale? Yes, currently we are on second ongoing private sale round II, since the round I was oversubscribed. In total there will be three rounds. We have a current price, which is $0.06 per token, on the launch day in December 10 it will be $0.1 per token. Currently we are very satisfied to have such a great engagement and eagerness from the public, we managed to attract private investors, corporate investors, funds and many more. There in an ongoing SOLX private sale. To participate you can visit soldex.ai or contact [email protected]

SOLX Frequently Asked Questions (FAQ)

  • Where is SOLX's headquarters?

    SOLX's headquarters is located at 230 Second Ave, Waltham.

  • What is SOLX's latest funding round?

    SOLX's latest funding round is Dead.

  • How much did SOLX raise?

    SOLX raised a total of $11.74M.

  • Who are the investors of SOLX?

    Investors of SOLX include Spotlight Innovation, MVM Partners, Management Buyout (MBO), TearLab and Boston University Technology Development.

  • Who are SOLX's competitors?

    Competitors of SOLX include ArthroSurface, AcuFocus, Spectranetics, Atria Medical, EyeTechCare and 11 more.

Compare SOLX to Competitors

A
AcuFocus

AcuFocus is an ophthalmic medical device company that develops and markets technologies for the improvement of near vision. The company's technology platform uses a small aperture - or pinhole - effect to allow focused light rays to reach the retina and bring objects into focus. Using this small aperture concept, two products have been developed: the Company's flagship product, the KAMRA corneal inlay, and the IC-8 IOL. The KAMRA inlay helps presbyopic patients restore their near vision while maintaining their distance vision. The IC-8 IOL* is specifically designed for patients with cataracts. In addition to these products, AcuFocus also distributes the AcuTarget HD diagnostic and surgical planning instrument. This instrument is used for a range of patients, including LASIK, cataract, dry eye and presbyopes.

E
EyeTechCare

EyeTechCare is developing non-invasive therapeutic medical devices for the ophthalmology market based on High-Intensity Focused Ultrasound (HIFU), a technology that allows ambulatory and rapid treatment to be performed, thereby limiting the cost and the risk to the patient. The company's first device, EyeOP1 (R), for the treatment of glaucoma, has been undergoing clinical trials in France and Europe.

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

N
NovaLign Orthopaedics

NovaLign Orthopaedics, formerly known as OsteoLign, is developing a minimally invasive solution for long bone fractures.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

M
Molnlycke Health Care

Molnlycke Health Care is a manufacturer of single-use surgical and wound care products. The company's products help patients feel less pain and aid healthcare professionals to safer and more efficient surgery.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.